IO Biotech, Inc. (IOBT)
IO Biotech, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Copenhagen, DK. The stock last traded at $0.01, down 27.59% on the session, giving a market capitalisation of $885,690. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of 0.0%. Its beta of 0.89 implies it has historically moved less than the broad market.
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.
IO Biotech, Inc. is most often compared with the following Healthcare names: